Biomarker Exploring Program, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital/Shanghai Clinical Research Center, Chinese Academy of Sciences, 966 Middle Huaihai Road, Shanghai 200031, China.
Biomarker Exploring Program, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital/Shanghai Clinical Research Center, Chinese Academy of Sciences, 966 Middle Huaihai Road, Shanghai 200031, China.
Clin Biochem. 2021 Jan;87:32-38. doi: 10.1016/j.clinbiochem.2020.10.008. Epub 2020 Oct 17.
Coronary artery disease (CAD) is an ischemic heart disease due to the narrowing of the coronary arteries resulting from atherosclerosis. Blood biomarkers have been well utilized for the diagnosis and prognosis of CAD. However, the value of biomarkers for evaluating coronary atherosclerosis remains to be clarified. This clinical investigation aimed to explore the potential value of biomarkers for evaluating the severity of coronary stenosis in CAD patients.
The extent of coronary atherosclerosis was accessed by the angiography-based quantitative measurement Gensini score (GS). Blood levels of Brain natriuretic peptide, Copeptin (CPP), Phosphodiesterase 9A, and Pentraxin3 (PTX3) were measured in 56 patients divided into three levels as low GS (n = 17), intermediate GS (n = 19) and high GS (n = 20) based on GS tertiles.
We found that plasma concentrations of CPP and PTX3 were significantly elevated in patients with high GS compared with the low GS group. In addition, Pearson correlation analysis showed that CPP and PTX3 were positively correlated with the GS. Furthermore, Receiver operating characteristics analysis demonstrated that both CPP and PTX3 exhibited discriminative capacities for evaluating the extent of coronary stenosis.
Laboratory tests of CPP and PTX3 via non-invasive means may provide novel information for risk stratification and disease management in CAD patients before invasive angiographic approaches. This study opens the door for enormous opportunities to explore new biomarkers with better efficiency, sensitivity and specificity as alternative/additional methods for evaluating the severity of coronary atherosclerosis in CAD patients in future research.
冠心病（CAD）是一种缺血性心脏病，由于动脉粥样硬化导致冠状动脉狭窄。血液生物标志物已被广泛用于 CAD 的诊断和预后。然而，生物标志物在评估冠状动脉粥样硬化程度方面的价值仍需阐明。本临床研究旨在探讨生物标志物在评估 CAD 患者冠状动脉狭窄严重程度方面的潜在价值。
通过基于血管造影的定量测量 Gensini 评分（GS）评估冠状动脉粥样硬化的程度。将 56 例患者根据 GS 三分位数分为低 GS（n=17）、中 GS（n=19）和高 GS（n=20）三组，测量脑钠肽、 copeptin（CPP）、磷酸二酯酶 9A 和 pentraxin3（PTX3）的血液水平。
我们发现，与低 GS 组相比，高 GS 组患者 CPP 和 PTX3 的血浆浓度显著升高。此外，Pearson 相关分析表明 CPP 和 PTX3 与 GS 呈正相关。此外，ROC 分析表明 CPP 和 PTX3 均具有评估冠状动脉狭窄程度的判别能力。
通过非侵入性方法进行 CPP 和 PTX3 的实验室检测，可能为 CAD 患者在进行有创血管造影检查之前提供风险分层和疾病管理的新信息。这项研究为未来研究中探索新的生物标志物提供了巨大的机会，这些生物标志物具有更好的效率、灵敏度和特异性，可以作为评估 CAD 患者冠状动脉粥样硬化严重程度的替代/附加方法。
